Xalkori (crizotinib) — United Healthcare
Anaplastic Large Cell Lymphoma (ALCL)
Initial criteria
- Diagnosis of anaplastic large cell lymphoma
- Tumor is ALK-positive
- Disease is relapsed or refractory
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Xalkori therapy
Approval duration
12 months